ACE and chronic kidney disease: Future directions should prioritize head-to-head comparisons of ACE inhibitors versus ARBs in homogeneous CKD subgroups, longer-term outcome studies that extend beyond surrogate markers, and exploration of strategies to optimize therapy in underrepresented groups such as the elderly, non-albuminuric CKD patients, and those with multiple comorbidities.